![RLSD09 [Anti-PA 3, DB90 5CT3.5.2]](http://www.family998.com/static/images/cells-no_picture.jpg)
-
平臺(tái)編號(hào)：bio-68409
-
國(guó)際編號(hào)：HB-8525?
-
細(xì)胞信息： RLSD09
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
RLSD09 [Anti-PA 3, DB90 5CT3.5.2]
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來源：小鼠
ATCC Number：HB-8525?
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：1mg Designations: RLSD09 [Anti-PA 3, DB90 5CT3.5.2]
Depositors: ?Cetus Corp.
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human prostate antigen (PA, 33000 dalton glycoprotein)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with purified PA from human semen.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water and supplemented with 1.5 g/L sodium bicarbonate. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: fetal bovine serum, 90%; DMSO, 10%
References: 3896: M'Timkulu T, et al. Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay. US Patent 4,690,890 dated Sep 1 1987
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來源：小鼠
ATCC Number：HB-8525?
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：1mg Designations: RLSD09 [Anti-PA 3, DB90 5CT3.5.2]
Depositors: ?Cetus Corp.
Isotype: IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human prostate antigen (PA, 33000 dalton glycoprotein)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with purified PA from human semen.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water and supplemented with 1.5 g/L sodium bicarbonate. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: fetal bovine serum, 90%; DMSO, 10%
References: 3896: M'Timkulu T, et al. Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay. US Patent 4,690,890 dated Sep 1 1987
